UCB's Global Corporate Website
Welcome to UCB in the United States

Aug

22

A Caregiver’s Perspective: Returning to School This Fall

Aug

17

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Aug

16

How Winners of the UCB Family Epilepsy Scholarship Prepare to Go Back to School

As students and parents prepare for a new school year, there can be a lot of stress  – from meeting new teachers and preparing for classes, to financial assistance and making new friends. For people living with epilepsy and their caregivers, the stress and worry surrounding back-to-school preparation is compounded.

Jun

13

UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

Apr

02

Advancing Our Mission to Cure Epilepsy

With nearly 30 years of experience in epilepsy, UCB can and will unlock what's possible for the millions of people living with epilepsy, so their reality can be free from seizures and the other debilitating and unpredictable impacts of the disease. Hear from Mike Davis, Head of U.S. Neurology and Rare, share our plan to impact the underlying causes of the disease and to discover, develop, and deliver highly differentiated medicines that will transform and, ultimately, cure the disease, so that people living with epilepsy can live their ideal life, every day.

Apr

01

UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Jan

19

UCB to acquire Zogenix

Dec

02

Working Toward a More Equitable Future: Addressing Barriers in the Hispanic Epilepsy Community

To better understand the experiences of Hispanic people with epilepsy and to improve our collective effort to break down barriers to equitable health outcomes, UCB is working with patients and their families, as well as health equity experts. Learn more.